title: Phase II study of weekly 24-hour intra-arterial high-dose infusion of 5-fluorouracil and folinic acid for liver metastases from colorectal carcinomas.
abstract: BACKGROUND
  A multicenter phase II trial was initiated in order to evaluate the weekly, high-dose 24-hour infusion of 5-fluorouracil (5-FU) plus folinic acid (FA) in patients with unresectable colorectal cancer hepatic metastases.
  
  
  METHODS
  A weekly hepatic arterial infusion (HAI) of FA 500 mg/m2 followed by a 24-hour infusion of 5-FU 2,600 mg/m2 (later reduced to 2,200 mg/m2) was given via a surgically implanted intra-arterial port system. One treatment cycle consisted of six weekly applications followed by a two-week rest period. Toxicity was assessed according to the WHO criteria. Chemotherapy was continued until disease progression or complete response occurred.
  
  
  RESULTS
  A total of 50 patients (40 chemonaive, 10 pre-treated) entered this trial. An objective tumor response occurred in 28 patients (56%), while 13 patients (26%) had stable disease. The median progression free survival was 12 months, and the median survival 22.3 months. Due to a high rate of gastrointestinal side-effects in the initial phase of the trial, the dosage of 5-FU was reduced to 2,200 mg/m2 for all subsequent patients. Diarrhea and nausea led to a dose reduction in 40% of applications and 24% of patients, respectively. One patient died of cardiac insufficiency unrelated to chemotherapy before response evaluation.
  
  
  CONCLUSIONS
  This HAI approach using high-dose 5-FU was relatively well tolerated when 2,200 mg/m2 instead of 2,600 mg/m2 was used. The activity of this regimen is promising and warrants further evaluation and modification.
authors.affiliation: Department of General and Vascular Surgery, Johann Wolfgang Goethe-University, Frankfurt, Germany. M.Lorenz@em.uni-frankfurt.de
authors.forename: M
authors.initials: M
authors.lastname: Lorenz
authors.forename: H H
authors.initials: HH
authors.lastname: Mueller
authors.forename: E
authors.initials: E
authors.lastname: Mattes
authors.forename: H J
authors.initials: HJ
authors.lastname: Gassel
authors.forename: T
authors.initials: T
authors.lastname: Junginger
authors.forename: H D
authors.initials: HD
authors.lastname: Saeger
authors.forename: H
authors.initials: H
authors.lastname: Schramm
authors.forename: E
authors.initials: E
authors.lastname: Staib-Sebler
authors.forename: G
authors.initials: G
authors.lastname: Vetter
authors.forename: S
authors.initials: S
authors.lastname: Heinrich
authors.forename: C H
authors.initials: CH
authors.lastname: Köhne
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary*; D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D015179:Colorectal Neoplasms / Q000473:pathology*; D018450:Disease Progression; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007261:Infusions, Intra-Arterial; D002955:Leucovorin / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D002955:Leucovorin; D005472:Fluorouracil